Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Febrile Neutropenia 5Neutropenia 4Breast Neoplasms 3Drug-Related Side Effects and Adverse Reactions 2Thrombocytopenia 1Rectal Neoplasms 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Intraocular Lymphoma 1Fever 1Colorectal Neoplasms 1Colonic Neoplasms 1Chemotherapy-Induced Febrile Neutropenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pegfilgrastim 1Gemcitabine 1Bevacizumab 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × pegfilgrastim × Classical hematology × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡